JAGX

Emerging Growth Conference Announcement: The 80th Emerging Growth Conference is scheduled for March 26 & 27, 2025, featuring presentations from various companies across growth sectors to engage with the investment community.

Conference Details and Participation: Attendees can register online, submit questions to presenting companies, and access video webcasts of the sessions, which aim to facilitate connections between public companies and potential investors.

Upcoming Stock Splits: Several companies are set to undergo stock splits or reverse stock splits from March 24 to March 28, including StoneX Group's three-for-two split and Angi Inc.'s one-for-ten reverse split, aimed at improving liquidity and compliance with Nasdaq requirements.

Company Details: Notable companies involved include Jaguar Health, Zoomcar Holdings, and NEC Corp., each implementing various splits to enhance share accessibility and meet regulatory standards, with trading on a split-adjusted basis expected shortly after the effective dates.

Trading Halt: Jaguar Animal Health's trading has been halted due to pending news, indicating potential significant developments regarding the company.

Recent Announcements: The company has announced a 1-for-25 reverse stock split and is advancing its drug Crofelemer for rare diseases, alongside adopting a limited duration stockholder rights plan.

Stock Performance: Jaguar Health Inc (JAGX) shares fell by 40.1% to 28 cents after announcing a 1-for-25 reverse stock split effective March 24, aimed at attracting institutional investors and maintaining Nasdaq compliance.

Investor Considerations: Investors evaluating JAGX should consider factors like valuation metrics, dividend payments, and potential buyback programs, as the stock has seen significant fluctuations with a 52-week high of $21.60 and a low of $0.32.

Emerging Growth Conference Announcement: The 79th Emerging Growth Conference will take place virtually on February 18 & 19, 2025, featuring presentations from various companies across growth sectors, focusing on their innovative products and long-term growth potential.

Registration and Participation Details: Interested participants can register for the conference online and submit questions to presenting companies via email, with all sessions conducted through video webcasts.

Jaguar Health's Clinical Trial Update: Jaguar Health and Napo Therapeutics have initiated a pediatric trial for crofelemer, with the first patient suffering from short bowel syndrome dosed, potentially leading to early access in Europe by 2025.

Leadership in Pediatric Gastroenterology: The trial is being led by Dr. Mohamad Miqdady at Sheikh Khalifa Medical City in the UAE, highlighting advancements in treatment options for gastrointestinal issues in children.

Emerging Growth Conference Announcement: The 77th Emerging Growth Conference is scheduled for December 4 & 5, 2024, featuring various companies across growth sectors presenting their innovative products and strategies to the investment community.

Registration and Participation Details: Attendees can register for the conference online, submit questions for presenting companies, and access video webcasts of the sessions, which aim to facilitate engagement between public companies and potential investors.

Stock Performance: Jaguar Health Inc.'s stock rose over 4% following the launch of its gelclair treatment for oral mucositis, a painful condition affecting many head and neck cancer patients undergoing chemotherapy.

Market Context: Despite the recent stock increase, Jaguar's shares have plummeted 86% this year, contrasting sharply with the S&P 500's 22% gain, highlighting ongoing challenges for the biotech company.

Stock Performance: Jaguar Health Inc.'s stock increased by 7% following the launch of its gelclair treatment for oral mucositis, a painful condition affecting head and neck cancer patients.

Health Impact: Oral mucositis, also known as "chemo mouth," is recognized as a significant adverse event in oncology, highlighting the importance of effective treatments for this condition.

Financial Performance: Jaguar Health reported a 16% increase in combined net revenue for Q2 2024, totaling approximately $2.72 million, with a focus on the growth of their prescription product Mytesi and plans for the upcoming launch of Gelclair for oral mucositis.

Clinical Developments: The company is advancing its clinical pipeline, particularly crofelemer, which has shown promising results in treating diarrhea related to cancer therapies, and is pursuing orphan drug designations for rare diseases such as microvillus inclusion disease and short bowel syndrome.

Jaguar Health Q2 2024 Results: Jaguar Health reported a second quarter earnings per share of -$4.04, significantly missing the analyst estimate of -$1.11, and generated revenue of $2.72 million, which was 30.93% below the expected $3.94 million.

InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly provide coverage of quarterly earnings reports, highlighting key financial metrics and comparisons to analyst estimates without human intervention.

Jaguar Health Inc Performance: Jaguar Health's shares fell by 10% to $1.08 after reporting a second-quarter loss of $4.04 per share, significantly worse than the expected loss of $1.11, with sales of $2.72 million also missing estimates.

Future Plans and Investor Considerations: The company plans to launch its FDA-approved Gelclair in October 2024 and continues developing treatments for rare diseases, while investors are advised to consider their strategies regarding stock performance amidst current market conditions.

Financial Performance: Jaguar Health reported a combined net revenue of approximately $2.72 million for Q2 2024, marking a 16% increase from Q1 2024 and a 2% increase from Q2 2023, alongside a decrease in net loss attributable to common shareholders.

Product Developments: The company is preparing for the commercial launch of Gelclair® in October 2024 and is conducting pivotal phase 3 trials for crofelemer aimed at treating cancer therapy-related diarrhea, with potential FDA discussions planned based on initial results.

Jaguar Health's Upcoming Webcast: Jaguar Health, Inc. will hold an investor webcast on August 13, 2024, to discuss its second-quarter financials and corporate updates, including the exploration of approval pathways for crofelemer in treating cancer-related diarrhea.

Phase 3 Clinical Trial Insights: The OnTarget clinical trial demonstrated crofelemer's efficacy in preventing cancer therapy-related diarrhea across various tumor types, highlighting its potential as a treatment option derived from a sustainable botanical source.

Health Care Stocks Performance: Health care stocks saw a slight increase, with the NYSE Health Care Index and Health Care Select Sector SPDR Fund both up 0.2%, while the iShares Biotechnology ETF decreased by 0.3%.

Corporate News Highlights: Medpace shares dropped 18% after lowering its revenue outlook, SeaStar Medical shares rose 2.6% following a successful treatment using Quelimmune, and Jaguar Health shares fell 58% due to disappointing phase 3 trial results for crofelemer.

Stock Offering Impact: Serve Robotics (SERV) is experiencing a decline in stock price after announcing a private offering of 2.5 million pre-funded warrants at $6 each, which dilutes existing shareholders' stakes and is significantly lower than the previous closing price of $8.77.

Market Reaction: As a result of the offering, SERV stock has dropped by 8.2%, with trading volume reaching 27 million shares compared to an average of 7.4 million, indicating investor dissatisfaction with the pricing and dilution effects.

• MultiMetaVerse Holdings Limited MMV saw a 224% increase in shares due to an acquisition agreement.
• GT Biopharma, Inc. GTBP rose by 146% following better-than-expected quarterly results.
• Tantech Holdings Ltd TANH jumped by 89.8%.
• Faraday Future Intelligent Electric Inc. FFIE gained 62.1% ahead of its financial report.
• CN Energy Group. Inc. CNEY surged by 58%.
• Scorpius Holdings, Inc. SCPX increased by 57.8%.
• NKGen Biotech, Inc. NKGN rose by 46% after clearance for a Phase 2 trial.
• Bruush Oral Care Inc. BRSH jumped by 41%.
• Rekor Systems, Inc. REKR gained 36% post-partnership announcement.
• MIRA Pharmaceuticals, Inc. MIRA rose by 34.3%.
• Scilex Holding Company SCLX gained 34%.
• Hims & Hers Health, Inc. HIMS rose by 30.5%.
• BYND Cannasoft Enterprises Inc. BCAN surged by 29.5%.
• Cheetah Mobile Inc. CMCM gained 24.3%.
• Concord Medical Services Holdings Limited CCM jumped by 23%.
• Wix.com Ltd. WIX rose by 21.6%.
• Sintx Technologies, Inc. SINT shares rose by 21.1%.
• Sutro Biopharma, Inc. STRO climbed by 17.6%.
• PTC Therapeutics, Inc. PTCT jumped by 17.2%.
• Cue Health Inc. HLTH gained 17.1%.
• NextDecade Corporation NEXT climbed by 16%.
• NuScale Power Corporation SMR rose by 15.5%.
• VinFast Auto Ltd. VFS gained 15%.
• Crown ElectroKinetics Corp. CRKN shares rose by 14.8%.
• Tellurian Inc. TELL gained 14%.
• Shineco, Inc. SISI shares climbed by 10.2%.
• Independent Bank Group, Inc. IBTX gained 8.5%.
• Doximity, Inc. DOCS surged by 5.1%.

• Akoustis Technologies, Inc. AKTS fell by 53.8%.
• Cheetah

Jaguar Health, Inc. Reverse Stock Split:

• Announced a 1-for-60 reverse stock split to comply with Nasdaq's listing standards.
• CEO Lisa Conte stated the split aims to attract institutional investors.
• Reported worse-than-expected first-quarter results with losses and lower sales.

Technical Analysis and Stock Price:

• Investors use moving averages and trend lines to predict stock price trajectory.
• Traders see being above the moving average as bullish and below as negative.
• Jaguar Health shares are down 42.5% at 14 cents following the announcement.